ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000235

Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs

Identifieur interne : 000235 ( PascalFrancis/Corpus ); précédent : 000234; suivant : 000236

Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs

Auteurs : Russell C. Callaghan ; James K. Cunningham ; Jenna Sykes ; Stephen J. Kish

Source :

Drug and alcohol dependence [ 0376-8716 ] ; 2012.

RBID : Pascal:12-0064798

Descripteurs français

Pascal (Inist)
- Métamfétamine, Facteur risque, Maladie de Parkinson, Amfétamine, Homme, Individu, Trouble motricité, Milieu hospitalier, Utilisation, Trouble moteur, Médicament, Incidence, Addiction, Santé publique, Dopamine, Cocaïne, Etude cohorte, Toxicomanie, Psychotrope, Stimulant SNC, Substance toxicomanogène.

English descriptors

KwdEn :
- Addiction, Amfetamine, CNS stimulant, Cocaine, Cohort study, Dopamine, Drug, Drug addiction, Drug of abuse, Hospital environment, Human, Incidence, Individual, Metamfetamine, Motility disorder, Motor system disorder, Parkinson disease, Psychotropic, Public health, Risk factor, Use.

Abstract

Background: Since methamphetamine and other amphetamine-type stimulants (meth/amphetamine) can damage dopaminergic neurons, researchers have long speculated that these drugs may predispose users to develop Parkinson's disease (PD), a dopamine deficiency neurological disorder. Methods: We employed a retrospective population-based cohort study using all linked statewide California inpatient hospital episodes and death records from January 1, 1990 through December 31, 2005. Patients at least 30 years of age were followed for up to 16 years. Competing risks analysis was used to determine whether the meth/amphetamine cohort had elevated risk of developing PD (ICD-9 332.0; ICD-10 G20) in comparison to a matched population-proxy appendicitis group and a matched cocaine drug control group. Individuals admitted to hospital with meth/amphetamine-related conditions (n = 40,472; ICD-9 codes 304.4, 305.7, 969.7, E854.2) were matched on age, race, sex, date of index admission, and patterns of hospital admission with patients with appendicitis conditions (n = 207,83 1; ICD-9 codes 540-542) and also individuals with cocaine-use disorders (n = 35,335; ICD-9 codes 304.2, 305.6, 968.5). Results: The meth/amphetamine cohort showed increased risk of PD compared to both that of the matched appendicitis group [hazard ratio (HR) = 1.76, 95% CI: 1.12-2.75, p = 0.017] and the matched cocaine group [HR ₌ 2.44,95% CI: 1.32-4.41, p=0.004]. The cocaine group did not show elevated hazard of PD compared to the matched appendicitis group [HR = 1.04, 95% CI: 0.56-1.93, p = 0.80]. Conclusion: These data provide evidence that meth/amphetamine users have above-normal risk for developing PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0376-8716`
A02	`01`			`@0 DADEDV`
A03		`1`		`@0 Drug and alcohol depend.`
A05				`@2 120`
A06				`@2 1-3`
A08	`01`	`1`	`ENG`	`@1 Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs`
A11	`01`	`1`		`@1 CALLAGHAN (Russell C.)`
A11	`02`	`1`		`@1 CUNNINGHAM (James K.)`
A11	`03`	`1`		`@1 SYKES (Jenna)`
A11	`04`	`1`		`@1 KISH (Stephen J.)`
A14	`01`			`@1 Centre for Addiction and Mental Health, 33 Russell St @2 Toronto, ON M5S 2S1 @3 CAN @Z 1 aut. @Z 3 aut. @Z 4 aut.`
A14	`02`			`@1 Dalla Lana School of Public Health, University of Toronto @2 Toronto, ON M5T 3M7 @3 CAN @Z 1 aut.`
A14	`03`			`@1 Department of Family and Community Medicine, The University of Arizona @2 Tucson, AZ 85719 @3 USA @Z 2 aut.`
A14	`04`			`@1 Departments of Psychiatry and Pharmacology, University of Toronto @2 Toronto, ON M5A 2N4 @3 CAN @Z 4 aut.`
A20				`@1 35-40`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 16471 @5 354000508827790060`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 3/4 p.`
A47	`01`	`1`		`@0 12-0064798`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Drug and alcohol dependence`
A66	`01`			`@0 IRL`
C01	`01`		`ENG`	@0 Background: Since methamphetamine and other amphetamine-type stimulants (meth/amphetamine) can damage dopaminergic neurons, researchers have long speculated that these drugs may predispose users to develop Parkinson's disease (PD), a dopamine deficiency neurological disorder. Methods: We employed a retrospective population-based cohort study using all linked statewide California inpatient hospital episodes and death records from January 1, 1990 through December 31, 2005. Patients at least 30 years of age were followed for up to 16 years. Competing risks analysis was used to determine whether the meth/amphetamine cohort had elevated risk of developing PD (ICD-9 332.0; ICD-10 G20) in comparison to a matched population-proxy appendicitis group and a matched cocaine drug control group. Individuals admitted to hospital with meth/amphetamine-related conditions (n = 40,472; ICD-9 codes 304.4, 305.7, 969.7, E854.2) were matched on age, race, sex, date of index admission, and patterns of hospital admission with patients with appendicitis conditions (n = 207,83 1; ICD-9 codes 540-542) and also individuals with cocaine-use disorders (n = 35,335; ICD-9 codes 304.2, 305.6, 968.5). Results: The meth/amphetamine cohort showed increased risk of PD compared to both that of the matched appendicitis group [hazard ratio (HR) = 1.76, 95% CI: 1.12-2.75, p = 0.017] and the matched cocaine group [HR ₌ 2.44,95% CI: 1.32-4.41, p=0.004]. The cocaine group did not show elevated hazard of PD compared to the matched appendicitis group [HR = 1.04, 95% CI: 0.56-1.93, p = 0.80]. Conclusion: These data provide evidence that meth/amphetamine users have above-normal risk for developing PD.
C02	`01`	`X`		`@0 002B18C05A`
C02	`02`	`X`		`@0 002B18C13`
C02	`03`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Métamfétamine @2 NK @2 FR @5 01`
C03	`01`	`X`	`ENG`	`@0 Metamfetamine @2 NK @2 FR @5 01`
C03	`01`	`X`	`SPA`	`@0 Metanfetamina @2 NK @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Facteur risque @5 02`
C03	`02`	`X`	`ENG`	`@0 Risk factor @5 02`
C03	`02`	`X`	`SPA`	`@0 Factor riesgo @5 02`
C03	`03`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 03`
C03	`03`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 03`
C03	`03`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 03`
C03	`04`	`X`	`FRE`	`@0 Amfétamine @2 NK @2 FR @5 04`
C03	`04`	`X`	`ENG`	`@0 Amfetamine @2 NK @2 FR @5 04`
C03	`04`	`X`	`SPA`	`@0 Anfetamina @2 NK @2 FR @5 04`
C03	`05`	`X`	`FRE`	`@0 Homme @5 05`
C03	`05`	`X`	`ENG`	`@0 Human @5 05`
C03	`05`	`X`	`SPA`	`@0 Hombre @5 05`
C03	`06`	`X`	`FRE`	`@0 Individu @5 06`
C03	`06`	`X`	`ENG`	`@0 Individual @5 06`
C03	`06`	`X`	`SPA`	`@0 Individuo @5 06`
C03	`07`	`X`	`FRE`	`@0 Trouble motricité @5 07`
C03	`07`	`X`	`ENG`	`@0 Motility disorder @5 07`
C03	`07`	`X`	`SPA`	`@0 Trastorno motilidad @5 07`
C03	`08`	`X`	`FRE`	`@0 Milieu hospitalier @5 08`
C03	`08`	`X`	`ENG`	`@0 Hospital environment @5 08`
C03	`08`	`X`	`SPA`	`@0 Medio hospitalario @5 08`
C03	`09`	`X`	`FRE`	`@0 Utilisation @5 09`
C03	`09`	`X`	`ENG`	`@0 Use @5 09`
C03	`09`	`X`	`SPA`	`@0 Uso @5 09`
C03	`10`	`X`	`FRE`	`@0 Trouble moteur @5 10`
C03	`10`	`X`	`ENG`	`@0 Motor system disorder @5 10`
C03	`10`	`X`	`SPA`	`@0 Trastorno motor @5 10`
C03	`11`	`X`	`FRE`	`@0 Médicament @5 11`
C03	`11`	`X`	`ENG`	`@0 Drug @5 11`
C03	`11`	`X`	`SPA`	`@0 Medicamento @5 11`
C03	`12`	`X`	`FRE`	`@0 Incidence @5 12`
C03	`12`	`X`	`ENG`	`@0 Incidence @5 12`
C03	`12`	`X`	`SPA`	`@0 Incidencia @5 12`
C03	`13`	`X`	`FRE`	`@0 Addiction @2 NM @5 13`
C03	`13`	`X`	`ENG`	`@0 Addiction @2 NM @5 13`
C03	`13`	`X`	`SPA`	`@0 Adicción @2 NM @5 13`
C03	`14`	`X`	`FRE`	`@0 Santé publique @5 17`
C03	`14`	`X`	`ENG`	`@0 Public health @5 17`
C03	`14`	`X`	`SPA`	`@0 Salud pública @5 17`
C03	`15`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 18`
C03	`15`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 18`
C03	`15`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 18`
C03	`16`	`X`	`FRE`	`@0 Cocaïne @2 NK @2 FR @2 FX @5 19`
C03	`16`	`X`	`ENG`	`@0 Cocaine @2 NK @2 FR @2 FX @5 19`
C03	`16`	`X`	`SPA`	`@0 Cocaína @2 NK @2 FR @2 FX @5 19`
C03	`17`	`X`	`FRE`	`@0 Etude cohorte @5 20`
C03	`17`	`X`	`ENG`	`@0 Cohort study @5 20`
C03	`17`	`X`	`SPA`	`@0 Estudio cohorte @5 20`
C03	`18`	`X`	`FRE`	`@0 Toxicomanie @5 21`
C03	`18`	`X`	`ENG`	`@0 Drug addiction @5 21`
C03	`18`	`X`	`SPA`	`@0 Toxicomanía @5 21`
C03	`19`	`X`	`FRE`	`@0 Psychotrope @2 FX @5 25`
C03	`19`	`X`	`ENG`	`@0 Psychotropic @2 FX @5 25`
C03	`19`	`X`	`SPA`	`@0 Psicotropo @2 FX @5 25`
C03	`20`	`X`	`FRE`	`@0 Stimulant SNC @5 26`
C03	`20`	`X`	`ENG`	`@0 CNS stimulant @5 26`
C03	`20`	`X`	`SPA`	`@0 Estimulante SNC @5 26`
C03	`21`	`X`	`FRE`	`@0 Substance toxicomanogène @5 27`
C03	`21`	`X`	`ENG`	`@0 Drug of abuse @5 27`
C03	`21`	`X`	`SPA`	`@0 Sustancia toxicomanógena @5 27`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 41`
C07	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 41`
C07	`06`	`X`	`FRE`	`@0 Dérivé de l'amphétamine @5 42`
C07	`06`	`X`	`ENG`	`@0 Amphetamine derivatives @5 42`
C07	`06`	`X`	`SPA`	`@0 Amfetamina derivado @5 42`
C07	`07`	`X`	`FRE`	`@0 Sympathomimétique @5 43`
C07	`07`	`X`	`ENG`	`@0 Sympathomimetic @5 43`
C07	`07`	`X`	`SPA`	`@0 Simpaticomimético @5 43`
C07	`08`	`X`	`FRE`	`@0 Catécholamine @5 45`
C07	`08`	`X`	`ENG`	`@0 Catecholamine @5 45`
C07	`08`	`X`	`SPA`	`@0 Catecolamina @5 45`
C07	`09`	`X`	`FRE`	`@0 Neurotransmetteur @5 46`
C07	`09`	`X`	`ENG`	`@0 Neurotransmitter @5 46`
C07	`09`	`X`	`SPA`	`@0 Neurotransmisor @5 46`
C07	`10`	`X`	`FRE`	`@0 Ester @5 47`
C07	`10`	`X`	`ENG`	`@0 Ester @5 47`
C07	`10`	`X`	`SPA`	`@0 Ester @5 47`
C07	`11`	`X`	`FRE`	`@0 Trouble neurologique @5 48`
C07	`11`	`X`	`ENG`	`@0 Neurological disorder @5 48`
C07	`11`	`X`	`SPA`	`@0 Trastorno neurológico @5 48`
N21				`@1 044`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 12-0064798 INIST
ET :	Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs
AU :	CALLAGHAN (Russell C.); CUNNINGHAM (James K.); SYKES (Jenna); KISH (Stephen J.)
AF :	Centre for Addiction and Mental Health, 33 Russell St/Toronto, ON M5S 2S1/Canada (1 aut., 3 aut., 4 aut.); Dalla Lana School of Public Health, University of Toronto/Toronto, ON M5T 3M7/Canada (1 aut.); Department of Family and Community Medicine, The University of Arizona/Tucson, AZ 85719/Etats-Unis (2 aut.); Departments of Psychiatry and Pharmacology, University of Toronto/Toronto, ON M5A 2N4/Canada (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Drug and alcohol dependence; ISSN 0376-8716; Coden DADEDV; Irlande; Da. 2012; Vol. 120; No. 1-3; Pp. 35-40; Bibl. 3/4 p.
LA :	Anglais
EA :	Background: Since methamphetamine and other amphetamine-type stimulants (meth/amphetamine) can damage dopaminergic neurons, researchers have long speculated that these drugs may predispose users to develop Parkinson's disease (PD), a dopamine deficiency neurological disorder. Methods: We employed a retrospective population-based cohort study using all linked statewide California inpatient hospital episodes and death records from January 1, 1990 through December 31, 2005. Patients at least 30 years of age were followed for up to 16 years. Competing risks analysis was used to determine whether the meth/amphetamine cohort had elevated risk of developing PD (ICD-9 332.0; ICD-10 G20) in comparison to a matched population-proxy appendicitis group and a matched cocaine drug control group. Individuals admitted to hospital with meth/amphetamine-related conditions (n = 40,472; ICD-9 codes 304.4, 305.7, 969.7, E854.2) were matched on age, race, sex, date of index admission, and patterns of hospital admission with patients with appendicitis conditions (n = 207,83 1; ICD-9 codes 540-542) and also individuals with cocaine-use disorders (n = 35,335; ICD-9 codes 304.2, 305.6, 968.5). Results: The meth/amphetamine cohort showed increased risk of PD compared to both that of the matched appendicitis group [hazard ratio (HR) = 1.76, 95% CI: 1.12-2.75, p = 0.017] and the matched cocaine group [HR ₌ 2.44,95% CI: 1.32-4.41, p=0.004]. The cocaine group did not show elevated hazard of PD compared to the matched appendicitis group [HR = 1.04, 95% CI: 0.56-1.93, p = 0.80]. Conclusion: These data provide evidence that meth/amphetamine users have above-normal risk for developing PD.
CC :	002B18C05A; 002B18C13; 002B17G
FD :	Métamfétamine; Facteur risque; Maladie de Parkinson; Amfétamine; Homme; Individu; Trouble motricité; Milieu hospitalier; Utilisation; Trouble moteur; Médicament; Incidence; Addiction; Santé publique; Dopamine; Cocaïne; Etude cohorte; Toxicomanie; Psychotrope; Stimulant SNC; Substance toxicomanogène
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central; Pathologie du système nerveux; Dérivé de l'amphétamine; Sympathomimétique; Catécholamine; Neurotransmetteur; Ester; Trouble neurologique
ED :	Metamfetamine; Risk factor; Parkinson disease; Amfetamine; Human; Individual; Motility disorder; Hospital environment; Use; Motor system disorder; Drug; Incidence; Addiction; Public health; Dopamine; Cocaine; Cohort study; Drug addiction; Psychotropic; CNS stimulant; Drug of abuse
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Nervous system diseases; Amphetamine derivatives; Sympathomimetic; Catecholamine; Neurotransmitter; Ester; Neurological disorder
SD :	Metanfetamina; Factor riesgo; Parkinson enfermedad; Anfetamina; Hombre; Individuo; Trastorno motilidad; Medio hospitalario; Uso; Trastorno motor; Medicamento; Incidencia; Adicción; Salud pública; Dopamina; Cocaína; Estudio cohorte; Toxicomanía; Psicotropo; Estimulante SNC; Sustancia toxicomanógena
LO :	INIST-16471.354000508827790060
ID :	12-0064798

Links to Exploration step

Pascal:12-0064798

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs</title>
<author><name sortKey="Callaghan, Russell C" sort="Callaghan, Russell C" uniqKey="Callaghan R" first="Russell C." last="Callaghan">Russell C. Callaghan</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for Addiction and Mental Health, 33 Russell St</s1>
<s2>Toronto, ON M5S 2S1</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Dalla Lana School of Public Health, University of Toronto</s1>
<s2>Toronto, ON M5T 3M7</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cunningham, James K" sort="Cunningham, James K" uniqKey="Cunningham J" first="James K." last="Cunningham">James K. Cunningham</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Family and Community Medicine, The University of Arizona</s1>
<s2>Tucson, AZ 85719</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sykes, Jenna" sort="Sykes, Jenna" uniqKey="Sykes J" first="Jenna" last="Sykes">Jenna Sykes</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for Addiction and Mental Health, 33 Russell St</s1>
<s2>Toronto, ON M5S 2S1</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for Addiction and Mental Health, 33 Russell St</s1>
<s2>Toronto, ON M5S 2S1</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Departments of Psychiatry and Pharmacology, University of Toronto</s1>
<s2>Toronto, ON M5A 2N4</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0064798</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0064798 INIST</idno>
<idno type="RBID">Pascal:12-0064798</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000235</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs</title>
<author><name sortKey="Callaghan, Russell C" sort="Callaghan, Russell C" uniqKey="Callaghan R" first="Russell C." last="Callaghan">Russell C. Callaghan</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for Addiction and Mental Health, 33 Russell St</s1>
<s2>Toronto, ON M5S 2S1</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Dalla Lana School of Public Health, University of Toronto</s1>
<s2>Toronto, ON M5T 3M7</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cunningham, James K" sort="Cunningham, James K" uniqKey="Cunningham J" first="James K." last="Cunningham">James K. Cunningham</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Family and Community Medicine, The University of Arizona</s1>
<s2>Tucson, AZ 85719</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sykes, Jenna" sort="Sykes, Jenna" uniqKey="Sykes J" first="Jenna" last="Sykes">Jenna Sykes</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for Addiction and Mental Health, 33 Russell St</s1>
<s2>Toronto, ON M5S 2S1</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name>
<affiliation><inist:fA14 i1="01"><s1>Centre for Addiction and Mental Health, 33 Russell St</s1>
<s2>Toronto, ON M5S 2S1</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Departments of Psychiatry and Pharmacology, University of Toronto</s1>
<s2>Toronto, ON M5A 2N4</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Drug and alcohol dependence</title>
<title level="j" type="abbreviated">Drug and alcohol depend.</title>
<idno type="ISSN">0376-8716</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Drug and alcohol dependence</title>
<title level="j" type="abbreviated">Drug and alcohol depend.</title>
<idno type="ISSN">0376-8716</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Addiction</term>
<term>Amfetamine</term>
<term>CNS stimulant</term>
<term>Cocaine</term>
<term>Cohort study</term>
<term>Dopamine</term>
<term>Drug</term>
<term>Drug addiction</term>
<term>Drug of abuse</term>
<term>Hospital environment</term>
<term>Human</term>
<term>Incidence</term>
<term>Individual</term>
<term>Metamfetamine</term>
<term>Motility disorder</term>
<term>Motor system disorder</term>
<term>Parkinson disease</term>
<term>Psychotropic</term>
<term>Public health</term>
<term>Risk factor</term>
<term>Use</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Métamfétamine</term>
<term>Facteur risque</term>
<term>Maladie de Parkinson</term>
<term>Amfétamine</term>
<term>Homme</term>
<term>Individu</term>
<term>Trouble motricité</term>
<term>Milieu hospitalier</term>
<term>Utilisation</term>
<term>Trouble moteur</term>
<term>Médicament</term>
<term>Incidence</term>
<term>Addiction</term>
<term>Santé publique</term>
<term>Dopamine</term>
<term>Cocaïne</term>
<term>Etude cohorte</term>
<term>Toxicomanie</term>
<term>Psychotrope</term>
<term>Stimulant SNC</term>
<term>Substance toxicomanogène</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Since methamphetamine and other amphetamine-type stimulants (meth/amphetamine) can damage dopaminergic neurons, researchers have long speculated that these drugs may predispose users to develop Parkinson's disease (PD), a dopamine deficiency neurological disorder. Methods: We employed a retrospective population-based cohort study using all linked statewide California inpatient hospital episodes and death records from January 1, 1990 through December 31, 2005. Patients at least 30 years of age were followed for up to 16 years. Competing risks analysis was used to determine whether the meth/amphetamine cohort had elevated risk of developing PD (ICD-9 332.0; ICD-10 G20) in comparison to a matched population-proxy appendicitis group and a matched cocaine drug control group. Individuals admitted to hospital with meth/amphetamine-related conditions (n = 40,472; ICD-9 codes 304.4, 305.7, 969.7, E854.2) were matched on age, race, sex, date of index admission, and patterns of hospital admission with patients with appendicitis conditions (n = 207,83 1; ICD-9 codes 540-542) and also individuals with cocaine-use disorders (n = 35,335; ICD-9 codes 304.2, 305.6, 968.5). Results: The meth/amphetamine cohort showed increased risk of PD compared to both that of the matched appendicitis group [hazard ratio (HR) = 1.76, 95% CI: 1.12-2.75, p = 0.017] and the matched cocaine group [HR <sub>=</sub>
 2.44,95% CI: 1.32-4.41, p=0.004]. The cocaine group did not show elevated hazard of PD compared to the matched appendicitis group [HR = 1.04, 95% CI: 0.56-1.93, p = 0.80]. Conclusion: These data provide evidence that meth/amphetamine users have above-normal risk for developing PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0376-8716</s0>
</fA01>
<fA02 i1="01"><s0>DADEDV</s0>
</fA02>
<fA03 i2="1"><s0>Drug and alcohol depend.</s0>
</fA03>
<fA05><s2>120</s2>
</fA05>
<fA06><s2>1-3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>CALLAGHAN (Russell C.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CUNNINGHAM (James K.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SYKES (Jenna)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>KISH (Stephen J.)</s1>
</fA11>
<fA14 i1="01"><s1>Centre for Addiction and Mental Health, 33 Russell St</s1>
<s2>Toronto, ON M5S 2S1</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Dalla Lana School of Public Health, University of Toronto</s1>
<s2>Toronto, ON M5T 3M7</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Family and Community Medicine, The University of Arizona</s1>
<s2>Tucson, AZ 85719</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Departments of Psychiatry and Pharmacology, University of Toronto</s1>
<s2>Toronto, ON M5A 2N4</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>35-40</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16471</s2>
<s5>354000508827790060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>3/4 p.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0064798</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Drug and alcohol dependence</s0>
</fA64>
<fA66 i1="01"><s0>IRL</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Since methamphetamine and other amphetamine-type stimulants (meth/amphetamine) can damage dopaminergic neurons, researchers have long speculated that these drugs may predispose users to develop Parkinson's disease (PD), a dopamine deficiency neurological disorder. Methods: We employed a retrospective population-based cohort study using all linked statewide California inpatient hospital episodes and death records from January 1, 1990 through December 31, 2005. Patients at least 30 years of age were followed for up to 16 years. Competing risks analysis was used to determine whether the meth/amphetamine cohort had elevated risk of developing PD (ICD-9 332.0; ICD-10 G20) in comparison to a matched population-proxy appendicitis group and a matched cocaine drug control group. Individuals admitted to hospital with meth/amphetamine-related conditions (n = 40,472; ICD-9 codes 304.4, 305.7, 969.7, E854.2) were matched on age, race, sex, date of index admission, and patterns of hospital admission with patients with appendicitis conditions (n = 207,83 1; ICD-9 codes 540-542) and also individuals with cocaine-use disorders (n = 35,335; ICD-9 codes 304.2, 305.6, 968.5). Results: The meth/amphetamine cohort showed increased risk of PD compared to both that of the matched appendicitis group [hazard ratio (HR) = 1.76, 95% CI: 1.12-2.75, p = 0.017] and the matched cocaine group [HR <sub>=</sub>
 2.44,95% CI: 1.32-4.41, p=0.004]. The cocaine group did not show elevated hazard of PD compared to the matched appendicitis group [HR = 1.04, 95% CI: 0.56-1.93, p = 0.80]. Conclusion: These data provide evidence that meth/amphetamine users have above-normal risk for developing PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B18C05A</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B18C13</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Métamfétamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Metamfetamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Metanfetamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Facteur risque</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Risk factor</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Factor riesgo</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Amfétamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Amfetamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Anfetamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Human</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Individu</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Individual</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Individuo</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Trouble motricité</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Motility disorder</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Trastorno motilidad</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Milieu hospitalier</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Hospital environment</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Medio hospitalario</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Utilisation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Use</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Uso</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Trouble moteur</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Motor system disorder</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Trastorno motor</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Médicament</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Drug</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Medicamento</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Incidence</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Incidence</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Incidencia</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Addiction</s0>
<s2>NM</s2>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Addiction</s0>
<s2>NM</s2>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Adicción</s0>
<s2>NM</s2>
<s5>13</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Santé publique</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Public health</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Salud pública</s0>
<s5>17</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Cocaïne</s0>
<s2>NK</s2>
<s2>FR</s2>
<s2>FX</s2>
<s5>19</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Cocaine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s2>FX</s2>
<s5>19</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Cocaína</s0>
<s2>NK</s2>
<s2>FR</s2>
<s2>FX</s2>
<s5>19</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Etude cohorte</s0>
<s5>20</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Cohort study</s0>
<s5>20</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Estudio cohorte</s0>
<s5>20</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Toxicomanie</s0>
<s5>21</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Drug addiction</s0>
<s5>21</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Toxicomanía</s0>
<s5>21</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Psychotrope</s0>
<s2>FX</s2>
<s5>25</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>Psychotropic</s0>
<s2>FX</s2>
<s5>25</s5>
</fC03>
<fC03 i1="19" i2="X" l="SPA"><s0>Psicotropo</s0>
<s2>FX</s2>
<s5>25</s5>
</fC03>
<fC03 i1="20" i2="X" l="FRE"><s0>Stimulant SNC</s0>
<s5>26</s5>
</fC03>
<fC03 i1="20" i2="X" l="ENG"><s0>CNS stimulant</s0>
<s5>26</s5>
</fC03>
<fC03 i1="20" i2="X" l="SPA"><s0>Estimulante SNC</s0>
<s5>26</s5>
</fC03>
<fC03 i1="21" i2="X" l="FRE"><s0>Substance toxicomanogène</s0>
<s5>27</s5>
</fC03>
<fC03 i1="21" i2="X" l="ENG"><s0>Drug of abuse</s0>
<s5>27</s5>
</fC03>
<fC03 i1="21" i2="X" l="SPA"><s0>Sustancia toxicomanógena</s0>
<s5>27</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Dérivé de l'amphétamine</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Amphetamine derivatives</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Amfetamina derivado</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Sympathomimétique</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Sympathomimetic</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Simpaticomimético</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>45</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>46</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Ester</s0>
<s5>47</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Ester</s0>
<s5>47</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Ester</s0>
<s5>47</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>48</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>48</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>48</s5>
</fC07>
<fN21><s1>044</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 12-0064798 INIST</NO>
<ET>Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs</ET>
<AU>CALLAGHAN (Russell C.); CUNNINGHAM (James K.); SYKES (Jenna); KISH (Stephen J.)</AU>
<AF>Centre for Addiction and Mental Health, 33 Russell St/Toronto, ON M5S 2S1/Canada (1 aut., 3 aut., 4 aut.); Dalla Lana School of Public Health, University of Toronto/Toronto, ON M5T 3M7/Canada (1 aut.); Department of Family and Community Medicine, The University of Arizona/Tucson, AZ 85719/Etats-Unis (2 aut.); Departments of Psychiatry and Pharmacology, University of Toronto/Toronto, ON M5A 2N4/Canada (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Drug and alcohol dependence; ISSN 0376-8716; Coden DADEDV; Irlande; Da. 2012; Vol. 120; No. 1-3; Pp. 35-40; Bibl. 3/4 p.</SO>
<LA>Anglais</LA>
<EA>Background: Since methamphetamine and other amphetamine-type stimulants (meth/amphetamine) can damage dopaminergic neurons, researchers have long speculated that these drugs may predispose users to develop Parkinson's disease (PD), a dopamine deficiency neurological disorder. Methods: We employed a retrospective population-based cohort study using all linked statewide California inpatient hospital episodes and death records from January 1, 1990 through December 31, 2005. Patients at least 30 years of age were followed for up to 16 years. Competing risks analysis was used to determine whether the meth/amphetamine cohort had elevated risk of developing PD (ICD-9 332.0; ICD-10 G20) in comparison to a matched population-proxy appendicitis group and a matched cocaine drug control group. Individuals admitted to hospital with meth/amphetamine-related conditions (n = 40,472; ICD-9 codes 304.4, 305.7, 969.7, E854.2) were matched on age, race, sex, date of index admission, and patterns of hospital admission with patients with appendicitis conditions (n = 207,83 1; ICD-9 codes 540-542) and also individuals with cocaine-use disorders (n = 35,335; ICD-9 codes 304.2, 305.6, 968.5). Results: The meth/amphetamine cohort showed increased risk of PD compared to both that of the matched appendicitis group [hazard ratio (HR) = 1.76, 95% CI: 1.12-2.75, p = 0.017] and the matched cocaine group [HR <sub>=</sub>
 2.44,95% CI: 1.32-4.41, p=0.004]. The cocaine group did not show elevated hazard of PD compared to the matched appendicitis group [HR = 1.04, 95% CI: 0.56-1.93, p = 0.80]. Conclusion: These data provide evidence that meth/amphetamine users have above-normal risk for developing PD.</EA>
<CC>002B18C05A; 002B18C13; 002B17G</CC>
<FD>Métamfétamine; Facteur risque; Maladie de Parkinson; Amfétamine; Homme; Individu; Trouble motricité; Milieu hospitalier; Utilisation; Trouble moteur; Médicament; Incidence; Addiction; Santé publique; Dopamine; Cocaïne; Etude cohorte; Toxicomanie; Psychotrope; Stimulant SNC; Substance toxicomanogène</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central; Pathologie du   système nerveux; Dérivé de l'amphétamine; Sympathomimétique; Catécholamine; Neurotransmetteur; Ester; Trouble neurologique</FG>
<ED>Metamfetamine; Risk factor; Parkinson disease; Amfetamine; Human; Individual; Motility disorder; Hospital environment; Use; Motor system disorder; Drug; Incidence; Addiction; Public health; Dopamine; Cocaine; Cohort study; Drug addiction; Psychotropic; CNS stimulant; Drug of abuse</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Nervous system diseases; Amphetamine derivatives; Sympathomimetic; Catecholamine; Neurotransmitter; Ester; Neurological disorder</EG>
<SD>Metanfetamina; Factor riesgo; Parkinson enfermedad; Anfetamina; Hombre; Individuo; Trastorno motilidad; Medio hospitalario; Uso; Trastorno motor; Medicamento; Incidencia; Adicción; Salud pública; Dopamina; Cocaína; Estudio cohorte; Toxicomanía; Psicotropo; Estimulante SNC; Sustancia toxicomanógena</SD>
<LO>INIST-16471.354000508827790060</LO>
<ID>12-0064798</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000235 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000235 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:12-0064798
   |texte=   Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs

Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri